Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Douxfils, Jonathan;Haguet, Hélène;Mullier, François;Chatelain, Christian;Dogné, Jean-Michel;et.al.
(2016) JAMA oncology — Vol. 2, n° 5, p. 625-632 (2016)

Files

DouxfilsJJAMAOncol2016.pdf
  • Open Access
  • Adobe PDF
  • 472.92 KB
Download

Details

Authors
  • Douxfils, Jonathan
    Author
  • Haguet, Hélène
    Author
  • Mullier, FrançoisUCLouvain
    Author
  • Chatelain, ChristianUCLouvain
    Author
  • Graux, CarlosUCLouvain
    Author
  • Dogné, Jean-Michel
    Author
Show more
Abstract
A phase 3 trial with ponatinib in patients with chronic myeloid leukemia (CML) was interrupted due to an important increase of vascular occlusive events. A similar risk was also suspected with nilotinib, another BCR-ABL tyrosine kinase inhibitor (TKI) used in patients with CML.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Douxfils, J., Haguet, H., Mullier, F., Chatelain, C., Graux, C., & Dogné, J.-M. (2016). Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. JAMA oncology, 2(5), 625-632. https://doi.org/10.1001/jamaoncol.2015.5932 (Original work published 2016)